https://www.selleckchem.com/products/enpp-1-in-1.html Primary cutaneous lymphomas encompass a wide spectrum of rare lymphoproliferative disorders originating in the skin, among which, mycosis fungoides (MF) is the most common subtype. The treatment of this disease is based on skin-directed therapies eventually in association with biologic response modifiers in the early phases, whereas in patients with the advanced stages, several therapeutic strategies can be used including mono and/or polychemotherapy and bone marrow transplantation. In recent years, the identification of specific markers (phenotypical, immunological, and molecular) has led to the development of several studies (including two randomized phase III trials). The results of these studies are modifying our therapeutic strategy toward a personalized treatment approach in which the clinical characteristics of the patients and tumor-node-metastasis-blood stage are considered together with the expression of specific markers (i.e., a CD30-positive expression for the use of brentuximab vedotin). This review will provide a comprehensive scenario of the main phenotypical, molecular, and immunological markers related to MF pathogenesis and disease evolution, which could represent the target for the development of innovative effective treatments in this disease.CO2 hydrogenation over Ni/SiO2 catalysts with and without Na additives was investigated in terms of the catalytic activity, selectivity of CO2 methanation and reaction mechanism. Na additives could cause the formation of Na2O species that might deposit on the Ni surface of Ni/SiO2 (NiNax/SiO2). When the Ni metal is partially covered with Na2O species, a highly positive charge on the Ni metal could occur compared to the original Ni/SiO2 catalyst. The addition of Na to the Ni/SiO2 catalyst could influence selectivity toward CO formation. The adsorbed formic acid is the major intermediate on the Ni/SiO2 catalyst during CO2 hydrogenation. The formic acid spec